{"id":"W4210298556","doi":"10.2165/00128413-200615270-00041","title":"Cipher Pharmaceuticals has received final approval from Health Canada for CIP-Fenofibrate,","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Medicine; Fenofibrate; Pharmacy; Drug approval; Pharmacology; Family medicine; Drug","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001162281,0.000678036,0.001020838,0.001169983,0.001004954,0.001255786,0.001004028,0.002581868,0.05604867],"category_scores_gemma":[0.00206042,0.000328558,0.0006767029,0.0004194453,0.0006766517,0.0004314297,0.0004085294,0.002197919,0.01504673],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002013115,"about_ca_system_score_gemma":0.006661998,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01192826,"about_ca_topic_score_gemma":0.03072976,"domain_scores_codex":[0.9992359,0.000109959,0.00004196678,0.00008959039,0.0003821305,0.0001405901],"domain_scores_gemma":[0.9983891,0.0002682745,0.0001453157,0.0001057537,0.0005205565,0.0005709288],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0124048,0.001190323,0.003287489,0.001305242,0.0001464219,0.00269216,0.0001312397,0.0007818015,0.1033004,0.007850642,0.3061773,0.5607321],"study_design_scores_gemma":[0.0059177,0.003621127,0.009691331,0.0001908291,0.0001788278,0.005848127,0.000062828,0.0007559206,0.03164762,0.0005300448,0.9414977,0.0000579813],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.1375897,0.07906006,0.008609698,0.04829712,0.009640648,0.004352522,0.02495762,0.004498412,0.6829942],"genre_scores_gemma":[0.326124,0.01925773,0.01285433,0.009384865,0.002899056,0.0006357537,0.01649229,0.0005403063,0.6118117],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.9880717,"threshold_uncertainty_score":0.1875014,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07076342288765271,"score_gpt":0.3745570026503249,"score_spread":0.3037935797626722,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}